Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.

By D. Henderson, E. Cagliero, C. Gray, R. Nasrallah, D. Hayden, D. Schoenfeld, D. Goff. American Journal of Psychiatry, 2000

729 citations recorded by the source corpus.

Subfields: Pediatrics, Perinatology and Child Health, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/6d4409c8e3f6027a54a209c828f412a3ff6dc8aa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pediatrics, Perinatology and Child Health

In Psychiatry and Mental health

F. Alsaraj

Citations in the corpus

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. (2001, background): “New-onset diabetes has been seen with both clozapine (64, 65) and olanzapine (65), and there are reports of increased plasma glucose in patients with preexisting diabetes following treatment with clozapine, olanzapine, and quetiapine (66, 67).”
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis (2010, background): “Weight gain is rapid in the first few weeks, and the rapid rate decreases gradually until the weight gain plateaus after several months, after 4-9 months for olanzapine and after 42-46 months for clozapine (Bai et al., 2009; Henderson et al., 2000; Kinon et al., 2005).”
Ten Putative Contributors to the Obesity Epidemic (2009, positive): “Recent studies document the risks of obesity: Henderson and colleagues demonstrated that weight gain associated with clozapine treatment continued for as long as 46 months was accompanied by a significant increase in triglyceride levels and a 37% increase in the incidence of Type 2 diabetes over the”
Pathogenesis of Type 2 Diabetes Mellitus (2015, background): “Clozapine Olanzapine Wight gain [172, 173] and adiposity [174] Risk of hyperglycemia is more in patients with obesity, age, ethnic status, and certain neuropsychiatric conditions [173].”
Physical health monitoring of patients with schizophrenia. (2004, background): “6% eventually received a diagnosis of type II diabetes (22).”
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. (2002, background): “mellitus has not been demonstrated (14), there have been several reports of hyperglycemia and diabetes mellitus”